IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.594 CHF | +2.61% |
|
+20.65% | +22.71% |
| May. 21 | Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| May. 21 | Swiss Stocks Flash Red Amid Economic Data Focus in Europe | MT |
| Sales 2024 * | 135M 150M | Sales 2025 * | 261M 289M | Capitalization | 464M 514M |
|---|---|---|---|---|---|
| Net income 2024 * | -407M -451M | Net income 2025 * | -349M -387M | EV / Sales 2024 * | 12.2 x |
| Net Debt 2024 * | 1.18B 1.31B | Net Debt 2025 * | 1.33B 1.47B | EV / Sales 2025 * | 6.89 x |
| P/E ratio 2024 * |
-1.74
x | P/E ratio 2025 * |
-2.64
x | Employees | 650 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +2.61% | ||
| 1 week | +20.65% | ||
| 1 month | +43.31% | ||
| 3 months | +16.22% | ||
| 6 months | +35.39% | ||
| Current year | +22.71% |
1 week
2.15
2.64
1 month
1.902.64
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 45 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2.594 | +2.61% | 505,160 |
| 24-05-30 | 2.528 | +7.57% | 730,165 |
| 24-05-29 | 2.35 | +4.44% | 690,160 |
| 24-05-28 | 2.25 | -1.32% | 412,870 |
| 24-05-27 | 2.28 | +6.05% | 249,803 |
Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-06-13
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.594
CHF
Average target price
1.692
CHF
Spread / Average Target
-34.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.71% | 514M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- IDIA Stock
